Pharmaceutical Investing AbbVie Announces U.S. FDA Approval of EPKINLY® in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
Pharmaceutical Investing LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer
Pharmaceutical Investing AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
Pharmaceutical Investing Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Pharmaceutical Investing ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
Pharmaceutical Investing The One & Only BOTOX® Cosmetic Day Returns November 19 with the Biggest Celebration of the Year
Pharmaceutical Investing AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib in Adults and Adolescents with Vitiligo
Pharmaceutical Investing Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
Pharmaceutical Investing The Confidence Project by BOTOX® Cosmetic Unveils This Year's Grant Recipients
Pharmaceutical Investing RINVOQ® Demonstrated Superiority Versus HUMIRA® for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
Pharmaceutical Investing U.S. Food and Drug Administration Approves Updated Indication Statement for RINVOQ® for the Treatment of Inflammatory Bowel Disease
Locksley Strengthens U.S. Defense Supply Chain Strategy with Appointment of Lockhead Martin Materials Leader to Advisory Board
